RIBOLIFE-B (06938) released its interim results, with a net profit attributable to the parent company of 20.301 million yuan, turning a profit compared to the same period last year.

RIBOLIFE-B (06938) announced its interim results for the six months ended June 30, 2026, reporting revenue of RMB 420 million, a year-on-year increase of 304.32%. The profit attributable to owners of the parent company was RMB 20.301 million, marking a turnaround from loss to profit; earnings per share were RMB 0.12. The announcement stated that the increase in revenue was primarily due to the development and commercialization of small interfering RNA (siRNA) therapy for metabolic dysfunction-associated fatty liver disease (MASH), the recognition of part of the authorized revenue under the global exclusive licensing collaboration with Madrigal, and the revenue recognized from the milestone reached in the collaboration with Boehringer Ingelheim, which were the key drivers of the revenue growth during the reporting period.